Ibuprofen

證據等級: L5

預測適應症: 7 個

Ibuprofen: From NSAID (Pain/Inflammation) to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Ibuprofen is a globally established nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1/COX-2 and is conventionally used for pain, fever, and inflammation; no Canadian market authorization record is present in this evidence pack. The TxGNN model predicts it may be relevant to Acromesomelic Dysplasia, Hunter-Thompson Type, a rare GDF5-gene-mutation skeletal dysplasia, but this is currently supported by 0 clinical trials and 0 publications — the prediction rests entirely on knowledge-graph embedding similarity, and the evidence pack’s own mechanistic rationale states there is no known biological connection between COX inhibition and this structural/developmental disorder.

Quick Overview

Item	Content
Original Indication	Not available from Canadian regulatory data (no licenses on file; drug currently 未上市/Not Marketed in Canada). Ibuprofen is universally known as an NSAID for pain, fever, and inflammation, but this is general pharmacological knowledge, not sourced from the regulatory dataset.
Predicted New Indication	Acromesomelic Dysplasia, Hunter-Thompson Type
TxGNN Prediction Score	99.74%
Evidence Level	L5 (model prediction only — no clinical trials, no literature)
Canada Market Status	✗ Not Marketed (未上市)
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed, drug-specific mechanism-of-action documentation is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on well-established pharmacological knowledge, Ibuprofen acts as a COX-1/COX-2 inhibitor, blocking prostaglandin synthesis to reduce pain, fever, and inflammation.

Acromesomelic Dysplasia, Hunter-Thompson Type, however, is caused by mutations in GDF5, a gene governing cartilage and joint morphogenesis. Its pathology is structural/developmental (abnormal skeletal patterning), not inflammation-mediated. The evidence pack’s own repurposing rationale is explicit on this point: there is no known mechanistic link between prostaglandin-pathway inhibition and GDF5-driven skeletal dysplasia.

In other words, the high TxGNN score (99.74%) most likely reflects graph-embedding proximity (e.g., shared metadata, co-occurring nodes, or structural similarity in the knowledge graph) rather than a plausible pharmacological pathway. Because Ibuprofen’s own original-indication and MOA records are themselves incomplete in this dataset, there is also no verified baseline to compare against. This prediction should be treated as a hypothesis-generating signal only, not as evidence of therapeutic relevance.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

No active Health Canada market authorizations (DINs) were found for Ibuprofen in this dataset — market status is recorded as 未上市 (Not Marketed), with 0 total licenses on file.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA/Health Canada label warnings and contraindications are recorded as a Blocking data gap (DG001) — this absence by itself prevents the candidate from entering the S1 safety pre-assessment stage, independent of the efficacy evidence discussed above.

Other Model-Predicted Candidates (Same Drug, Not Detailed Above)

For context, TxGNN generated several similarly-scored rare skeletal/developmental disease predictions for Ibuprofen in this run, none of which have clinical trial or literature support and all of which carry the same “Hold” recommendation:

Rank	Predicted Disease	TxGNN Score	Evidence Level	Decision
2	Brachyolmia-amelogenesis imperfecta syndrome	99.71%	L5	Hold
3	Myosclerosis	99.68%	L5	Hold
4	Brachyolmia	99.67%	L5	Hold
5	Brachydactyly-syndactyly syndrome	99.66%	L5	Hold
6	Pseudoachondroplasia	99.66%	L5	Hold
7	Colobomatous microphthalmia-rhizomelic dysplasia syndrome	99.60%	L5	Hold

The clustering of Ibuprofen’s top predictions around rare structural/skeletal dysplasias — rather than inflammation-related conditions — further supports the interpretation that these scores reflect knowledge-graph artifacts rather than genuine mechanistic candidates.

Conclusion and Next Steps

Decision: Hold

Rationale:

The prediction has no clinical trial or literature support (Evidence Level L5), and the evidence pack’s own mechanistic rationale states there is no known biological link between Ibuprofen’s COX-inhibition mechanism and this GDF5-driven skeletal dysplasia.
A Blocking-severity data gap (missing TFDA/Health Canada label warnings and contraindications) independently prevents this candidate from entering safety pre-assessment, and the drug currently has no active Canadian market authorization.

To proceed, the following is needed:

Health Canada / TFDA product monograph data (warnings, contraindications) to resolve the Blocking data gap (DG001)
Confirmed original indication and MOA data for Ibuprofen (DG002)
Any preclinical or mechanistic studies specifically linking prostaglandin-pathway modulation to GDF5-related skeletal development, if such a hypothesis is to be pursued further
Given the consistent lack of mechanistic and empirical support across all top-ranked predictions for this drug, reprioritization toward other TxGNN candidates with plausible mechanistic rationale is recommended before committing further review resources here
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.